Twinject, a novel epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions (anaphylaxis), was launched in the US and Canada in 2005. It is the first and only product approved by the FDA and Health Canada that contains two doses of epinephrine in a single, compact device for self-administration.
The Verus/UCB agreement includes an upfront payment to Verus, along with future launch and sales milestone payments, and royalties based on sales of Twinject (0.3mg and 0.15mg versions) and Twinject line extensions under development by Verus.
In addition, UCB has an option to commercialize the entire Twinject product line in all other territories beyond Europe (excluding the US and Canada) and an option to commercialize certain next-generation products under development by Verus for the emergency treatment of anaphylaxis.
“The agreement with Verus allows us the opportunity to build a European leadership position in an attractive, high-growth market showing strong synergies with UCB’s solid allergy business,” stated Bill Robinson, executive vice president of global operations at UCB. “UCB will now move toward initiating the European regulatory process for this novel product for the emergency treatment of anaphylaxis.”